NL-OMON53561尚未招募不适用
A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer - 20200469 (DeLLphi-303)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- Amgen
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Participant has provided informed consent/assent prior to initiation of any
- •study specific activities/procedures
- •Age greater than or equal to 18 years old at the same time of signing the
- •informed consent
- •Participants with histologically or cytologically confirmed Extended Stage
- •Small Cell Lung Cancer (ES-SCLC) and no prior systemic treatment for ES-SCLC
- •other than protocol defined standard of care first line therapy prior to
- •enrollment. Subjects with prior treatment for limited stage SCLC (LS-SCLC) are
- •Eastern Cooperative Oncology Group (ECOG) 0 to 1
- •Participants with treated asymptomatic brain metastases are eligible provided
- •they meet defined criteria
- •Adequate organ function as defined in protocol
- •Please refer to section 5.1 of the protocol for the full list of inclusion
- •criteria and any changes in these following protocol amendment 3.
排除标准
- •History of other malignancy within the past 2 years with exceptions
- •Major surgery within 28 days of study day 1
- •Untreated or symptomatic brain metastases and leptomeningeal disease
- •Please refer to section 5.2 of the protocol for the full list of exclusion
- •criteria and any changes in these following protocol amendment 3.
研究者
相似试验
进行中（未招募）
1 期
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)Small Cell Lung CancerJPRN-jRCT2031220086Tagashira Shuzo50
招募中
1 期
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapyExtensive Stage Small Cell Lung CancerJPRN-jRCT2031220277Tagashira Shuzo340
已完成
2 期
Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated Castrate Resistant Prostate Cancer1003859410036958Prostate CancerNL-OMON33942Amgen10
招募中
1 期
A Phase I Study to Evaluate the Safety and Efficacy of Mesenchymal Stromal Cells (MSC) for Treating Chronic Obstructive Pulmonary Disease (COPD)COPDRespiratory - Chronic obstructive pulmonary diseaseACTRN12614000731695Royal Perth Hospital10
进行中（未招募）
2 期
The Safety and Efficacy of THVD-102, a combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis.ACTRN12615000873527TheraVida, Inc21